Terms: = Kidney tumors AND MITF, WS2A, ENSG00000187098, 4286 AND Treatment
16 results:
1. High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M; Schmidt LS; Wilson KM; Ricketts CJ; Sourbier C; Vocke CD; Wei D; Crooks DR; Yang Y; Gibbs BK; Zhang X; Klumpp-Thomas C; Chen L; Guha R; Ferrer M; McKnight C; Itkin Z; Wangsa D; Wangsa D; James A; Difilippantonio S; Karim B; Morís F; Ried T; Merino MJ; Srinivasan R; Thomas CJ; Linehan WM
J Exp Clin Cancer Res; 2023 Apr; 42(1):99. PubMed ID: 37095531
[TBL] [Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
[TBL] [Abstract] [Full Text] [Related]
3. MiT/TFE Family Renal Cell Carcinoma.
Tang J; Baba M
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672892
[TBL] [Abstract] [Full Text] [Related]
4. The complex relationship between mitf and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Ballotti R; Cheli Y; Bertolotto C
Mol Cancer; 2020 Dec; 19(1):170. PubMed ID: 33276788
[TBL] [Abstract] [Full Text] [Related]
5. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract] [Full Text] [Related]
7. Familial kidney Cancer: Implications of New Syndromes and Molecular Insights.
Carlo MI; Hakimi AA; Stewart GD; Bratslavsky G; Brugarolas J; Chen YB; Linehan WM; Maher ER; Merino MJ; Offit K; Reuter VE; Shuch B; Coleman JA
Eur Urol; 2019 Dec; 76(6):754-764. PubMed ID: 31326218
[TBL] [Abstract] [Full Text] [Related]
8. Progress of small ubiquitin-related modifiers in kidney diseases.
Li O; Ma Q; Li F; Cai GY; Chen XM; Hong Q
Chin Med J (Engl); 2019 Feb; 132(4):466-473. PubMed ID: 30707172
[TBL] [Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitors in mitf family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract] [Full Text] [Related]
10. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract] [Full Text] [Related]
11. Xp11 Translocation Renal Cell Carcinoma and the Mesenchymal Counterparts: An Evolving Concept with Novel Insights on Clinicopathologic Features, Prognosis, treatment, and Classification.
Wang XT; Xia QY; Zhou XJ; Rao Q
Crit Rev Oncog; 2017; 22(5-6):481-497. PubMed ID: 29604926
[TBL] [Abstract] [Full Text] [Related]
12. Oncotargets in different renal cancer subtypes.
Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
[TBL] [Abstract] [Full Text] [Related]
13. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics.
Linehan WM
Genome Res; 2012 Nov; 22(11):2089-100. PubMed ID: 23038766
[TBL] [Abstract] [Full Text] [Related]
14. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
[TBL] [Abstract] [Full Text] [Related]
15. Renal cell carcinoma with mitf/TFE3 translocation in children: report of a case at the stage of lymph node involvement.
Fall B; Sarr A; Sow Y; Diao B
Afr J Paediatr Surg; 2011; 8(3):317-9. PubMed ID: 22248899
[TBL] [Abstract] [Full Text] [Related]
16. Canine malignant melanoma alpha-3 integrin binding peptides.
Aina OH; Maeda Y; Harrison M; Zwingenberger AL; Walker NJ; Lam KS; Kent MS
Vet Immunol Immunopathol; 2011 Sep; 143(1-2):11-9. PubMed ID: 21722969
[TBL] [Abstract] [Full Text] [Related]
